Trial Profile
A Phase II study of intratumoral injection of interleukin-12 plasmid and in vivo electroporation in patients with Merkel cell carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Tavokinogene telseplasmid (Primary)
- Indications Merkel cell carcinoma
- Focus Therapeutic Use
- Sponsors OncoSec Medical
- 15 Oct 2019 Results published in OncoSec Medical Incorporated Media Release.
- 03 Oct 2019 Results published in the Clinical Cancer Research.
- 24 Feb 2017 Status changed from active, no longer recruiting to completed.